Multimmune

Executive Summary

Multimmune GmbH is a private, clinical-stage biopharmaceutical company headquartered in Munich, Germany, specializing in the development of broad-spectrum cancer theranostics. Founded in 2008, the company's proprietary technology exploits the tumor-specific expression of membrane-bound heat shock protein 70 (Hsp70), which is found on a large proportion of cancer cells but absent on healthy cells. This unique biomarker enables the creation of both diagnostic and therapeutic agents that target a wide range of cancers. The company is currently in Phase 1 clinical development, focusing on validating its lead therapeutic candidate and companion diagnostic in patients. Multimmune's approach offers the potential to provide a unified platform for cancer detection and treatment, addressing significant unmet needs in oncology. Despite its innovative technology, the company remains at an early stage with limited public details regarding funding, valuation, or specific pipeline programs.

Upcoming Catalysts (preview)

• TBDPhase 1 Clinical Data Readout65% success
• TBDDiagnostic Assay Development Milestone70% success
• TBDStrategic Partnership or Licensing Deal50% success